GlassScriptPhysician profile
Richard A Nicklas
NPI 1467412510
$1,217.30
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $740 · 2020: $280 · 2021: $198.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $342.23 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $313.95 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $166.08 | 2019-2021 | |
| Genzyme Corporation | $138.44 | 2019-2020 | |
| Alk-Abello, INC | $60.57 | 2019 | |
| Genentech USA, INC. | $58.19 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $42.46 | 2019-2021 | |
| Kaleo, INC. | $39.17 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $36.47 | 2019-2021 | |
| Optinose US, INC. | $19.74 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Nicklas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.